Reda A. Mahmoud

ORCID: 0000-0001-9737-5551
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Drug Solubulity and Delivery Systems
  • Advancements in Transdermal Drug Delivery
  • Advanced Drug Delivery Systems
  • Crystallography and molecular interactions
  • Agricultural pest management studies
  • Lipid Membrane Structure and Behavior
  • Ocular Surface and Contact Lens
  • Plant Micronutrient Interactions and Effects
  • Dermatology and Skin Diseases
  • Glycosylation and Glycoproteins Research
  • Peptidase Inhibition and Analysis
  • Analytical Methods in Pharmaceuticals
  • Monoclonal and Polyclonal Antibodies Research
  • Animal Nutrition and Physiology
  • Crystallization and Solubility Studies
  • Computational Drug Discovery Methods

Al-Azhar University
2021-2024

Zagazig University
2017

Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow individuals with type 2 diabetes mellitus. Nevertheless, can upper respiratory tract infections, diarrhea, nausea, hypoglycemia, poor tolerability when taken orally regularly due...

10.1016/j.ijpx.2024.100232 article EN cc-by-nc-nd International Journal of Pharmaceutics X 2024-02-04

Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as first-line treatment for patients with advanced or metastatic non-small cell lung, colon, and breast cancer. GFT exhibits low solubility hence oral bioavailability, which restricts its clinical application. One of the most important trends in overcoming such problems use vesicular system. Cubosomes are considered one systems to improve bioavailability. In this study, cubosomal nanoparticles (GFT-CNPs) were prepared by emulsification...

10.3390/pharmaceutics15020680 article EN cc-by Pharmaceutics 2023-02-17

Hyperlipidemia is still the leading cause of heart disease in patients with hypertension. The purpose this study to make rosuvastatin calcium (ROS) and atenolol (AT) bilayer tablets treat coexisting dyslipidemia hypertension a single product. ROS was chosen for immediate-release layer constructed tablets, whereas AT sustained-release layer. solid dispersion sorbitol (1:3 w/w) utilized while hydroxypropyl methylcellulose (HPMC), ethylcellulose (EC), sodium bicarbonate were incorporated into...

10.3390/pharmaceutics14081629 article EN cc-by Pharmaceutics 2022-08-04

Abstract Cilostazol, an anti-platelet aggregation medicine, is also known to have vasodilation properties and commonly used for treating muscle soreness cramps by increasing the oxygen supply. The medication has limited oral bioavailability, prone pre-systemic metabolism, poorly soluble in aqueous media. A transdermal administration was planned increase drug’s solubility therapeutic efficacy. current work intended develop cilostazol niosome-loaded gel, which prepared, with use of Fourier...

10.1515/ntrev-2024-0066 article EN cc-by Nanotechnology Reviews 2024-01-01
Coming Soon ...